Special Alert : WASATCH PHARMACEUTICAL=
S (OTCBB: WSCH) |
|  | 
| TOP 4 REASONS TO BUY WSCH=
|  | | 1. | The products and medical therapies developed by WSCH rep=
resent possibly the most important breakthrough in the field of Der=
matology in the last fifty years. | | 2. | WSCH anticipat=
es FDA approval on seven over-the-counter products within the next =
year, which will provide significant revenue in the retail drug market. | | 3.<=
/font> | WSCH has experienced a success rate of 90% during clinical studies, completely eliminating skin disease from 90% of=
all patients treated. | | 4. | By year five, WSCH plan=
s to have annualized revenue over $525 million and over $125 mil=
lion in EBIT. This does not take into account income from OTC pr=
oducts which will be substantial. | 
| <=
font face=3D"Times New Roman" style=3D"font-size: 13pt"> =
PROJECTIONS, =
OBJECTIVES AND STATISTICS &=
nbsp; &nb=
sp; =
; &=
nbsp; &nb=
sp; =
; Over a five year period, AISC (WSCH's subsidiary) plans to establish =
350 clinics in over 100 major population areas. The company plans=
to hire over 150 medical doctors for these clinics, train over 1,000 medi=
cal assistants and treat over 2,000,000 patients. Also by year five=
, WSCH plans to have annualized over $525 million in revenue and over $=
125 million in EBIT. This does not take into account income from OTC p=
roducts which will be substantial. As of 1991, there were ap=
proximately 14 million chronic acne and eczema patients annually in=
the United States, with the highest percentage between 18 to 44 year=
s of age. The actual number of patients with any type of acne Is=
significantly higher. Seven billion dollars is spent annuall=
y on dermatological pharmaceutical products for these disorders.<=
/span> In 1994, the teen population reached 25 million. Duri=
ng the next decade, it will grow at nearly twice the rate of =
the overall population (according to U.S. Census Bureau projectio=
ns). Acne patients are primarily teenagers, whereas eczema patie=
nts range from infants to the elderly. |
| <=
td vAlign=3Dtop align=3Dleft width=3D277 rowspan=3D6 height=3D1>| SYMBOL:=
| &=
nbsp; WSCH | | &nbs=
p; CURRENT PRICE: | $0.059 | | =
; 52 WEEK HIGH: | $27.50 | | &=
nbsp; 52 WEEK LOW: | $0.056<=
/b> |
|
|  |
| COMPANY BACKGROUND<=
/font> |
| Wasatch Pharmaceutical, Inc. =
is a fourteen year old company with a record of outstanding achievements i=
n the field of Dermatology. Dermatology. Under the name of its subsid=
iary, American Institute of Skin Care (AISC), Wasatch has operated =
two prototype clinics for the last five years where the products and medic=
al therapies have been tested and proven on hundreds of patients. The Comp=
any's activities have been centered on research in the area of serious =
skin diseases. A concurrent discov=
ery and benefit is WSCH's dramatic success in the area of skin rejuvenatio=
n. | | Seeing the high growth potential from ma=
jor funding, WSCH elected to become a public company less than two =
years ago. Wasatch's major success=
es in the area of skin diseases include: | | Cystic Acne, Eczema, Seborrhea, Contact Dermatitis, Molluscum, Folliculit=
is, Acne Rosacea and less prevalent skin diseases. | Interestingly, these skin disorders account for more than 7=
0% of all business in the field of dermatology for which there are ver=
y few (if any) safe, effective therapies like those developed by Wasatc=
h. | | Because the therapies developed by W=
asatch dominate this area of medicine, WSCH has elected to market i=
ts products via company-owned clinics throughout the United States. T=
his decision has resulted in the establishment of two research clinics<=
/b> in Utah for the purpose of implementing procedures within the clinics =
pursuant to testing and confirming the results that were achieved in past =
clinical trials. Due to its success rate of 90% on hundreds of p=
atients over a five year period, WSCH's clinics are now on line with i=
nsurance providers independent of HMOs. Efforts to establish Preferred Pro=
vidership status with HMOs are presently being pursued. |
<=
/div> | | THIS J=
UST IN : WSCH BREAKING NEWS |
| Wasatch Pharmaceu=
tical Inc. Announces a New Physician Marketing Campaign and Listing On Ger=
man Stock Exchanges MURRAY, Utah--(BUSINESS WIRE)--Nov. 27,=
2001--Wasatch Pharmaceutical Inc. (OTCBB:WSCH - news) CEO Gary Heesch announced today a marketing campaign dir=
ected to physicians. A direct link has been established on a physician rec=
ruiting Web site making available therapies for the treatment of cystic ac=
ne, acne, folliculitis and skin rejuvenation. Physicians will find the ben=
efits of these treatment therapies by logging on to the "X Acne&qu=
ot; link at the Physician Search website. This physician search Web si=
te typically receives over 200,000 hits per month. Mr. Heesch remin=
ded, "Our treatment therapy products are also available via the AISC =
Online Store."Th=
ese skin treatment products come in kit form providing a 90-day supply to =
patients for the full treatment program. Included in the kit is an instruc=
tional video on the treatment therapy allowing the patient to use these pr=
oducts in their home. The therapies, when used as instructed, achieve a success rate of eradication in excess of 90% with no side effects of any =
consequence. Previously, these therapies and associated products were =
only available through the two prototype clinics in Utah. The availability=
of these products will open the way for family practitioners, pediatricia=
ns, internists and other primary care physicians to retain their patients =
under their care during the treatment of these common skin disorders. T=
he benefit to insurance providers is the potential to save millions of dol=
lars in reimbursement costs by freeing the physician and the patient from =
ongoing treatment. In the =
coming year, six additional therapies will be made available for a =
broad range of skin disorders that are badly in need of successful therapi=
es. Gary Heesch also announced=
the listing of Wasatch Pharmaceutical stock on the Frankfurt and Berli=
n Exchanges in Germany. Active trading on these exchanges will take pl=
ace upon the completion of a research report in Germany. Said Mr. Heesch, =
"We feel this is a significant event as Wasatch will gain wider ex=
posure as a leader in dermatology and will put buying pressu=
re on its stock to reflect the true value of a company that has=
committed years of research and development of products that allow people=
with serious skin disorders to live normal and more productive lives.&quo=
t; There may be forward-lookin=
g statements in this release. Investors are cautioned that such forward-lo=
oking statements involve risks and uncertainties, including, without limit=
ation, continued acceptance of the Company's products, increased levels of=
competition, new products introduced by competitors, changes in the rates=
of subscriber acquisition and retention, and other risks detailed from ti=
me to time in the Company's periodic reports filed with the Securities and=
Exchange Commission. | A LOOK AT THE COMPETITION | | Dermatologists are the primary competitors of WSCH's cli=
nics. Dermatologists specialize in the treatment of skin disorders and pre=
scribe medications to treat the disorder. However, competing products addr=
ess the symptoms of acne and eczema, not the cause. The=
competition's skin care treatments include prescription medications (oral=
and external use drugs prescribed by dermatologists and other doctors) an=
d over-the-counter products. Several com=
mon prescription medications include: 1)=
E-Mycin for oral and topical use, 2) Cleocin for oral and topical use, 3)=
Tetracycline for oral and topical use, and 4) Accutane for oral use only.=
Over-the-counter acne medications include:&nbs=
p;
1) Clearasil and Oxy creams, 2) generic brand creams, 3) medica=
ted pads, and 4) medicated soaps. Many of th=
e competition's oral medications have serious side effects. Costs for competing treatments range from $2.50 for medicated soap=
s to $200 for Accutane oral medication prescription. Treatments are on-goi=
ng. Over time a person can spend an unlimited amount of money =
on such treatments. An example would be someone who spent $1,500 for =
a 22 week program of Accutane which includes blood testing. Another e=
xample would be someone who has had acne for many years and has spent in e=
xcess of $34,000. At this time there is =
no known competitor who treats the causes of these skin disorders and =
no competitor can claim a success rate equal to that of Wasatch's t=
reatments. | A FINAL WORD ABOUT WSCH | =
W=
ith a proven success rate of 90% in a field that affects so many of our li=
ves, Wasatch has clearly positioned itself in a market hungry and despe=
rate for successful products and treatment. WSCH has recently exp=
anded its marketing presence (as seen in the above press release) and will=
continue to aggressively broaden awareness over the near term. The listin=
g of WSCH on the German stock exchange is another sign of the compa=
ny's credibility and ambitious plans to establish itself as a major glo=
bal player in the field of dermatology. WSCH =
has taken on a completely different approach. By addressing the cause=
s of skin disorders rather than the symptoms, WSCH will help to successful=
ly eliminate skin disease altogether. Given the following:1. Successful 14-year history and plans for expansion
2. Impressi=
ve revenue projections ($525 million+ annualized by year 5 and $125 m=
illion in EBIT)
3. Virtually unmatched success rate of 90%... ...and so much more, WSCH will certainly be watched by savvy inve=
stors for some time to come. | To be removed from future mailings, please reply=
to this email with "Remove" in the subject line | =
DISCLAIMER:
Information within this ema=
il contains "forward looking statements" within the meaning of S=
ection 27A of the Securities Act of 1933 and Section 21B of the Securities=
Exchange Act of 1934. Any statements that express or involve discussions =
with respect to predictions, expectations, beliefs, plans, projections, ob=
jectives, goals, assumptions or future events or performance are not state=
ments of historical fact and may be "forward looking statements."=
;
Forward looking statements are based on expectations, estimates=
and projections at the time the statements are made that involve a number=
of risks and uncertainties which could cause actual results or event=
s to differ materially from those presently anticipated. Forward looking s=
tatements in this action may be identified through the use of words such a=
s "projects", "foresee", "expects", "wi=
ll," "anticipates," "estimates," "beli=
eves," "understands" or that by statements indicating certa=
in actions "may," "could," or "might" occur.=
All information provided within this email pertaining to investing,=
stocks, securities must be understood as information provided and not inv=
estment advice. Emerging Growth Stock Alert advises all readers and subscr=
ibers to seek advice from a registered professional securities repres=
entative before deciding to trade in stocks featured within this email.&nb=
sp; None of the material within this report shall be construed as any kind=
of investment advice.
In compliance with the Securities Act of 1=
933, Section17(b), Emerging Growth Stock Alert discloses the receipt of $5=
0,000 cash from a third party for the publication of this report and addit=
ional services related to WSCH. Be aware of an inherent conflict of i=
nterest resulting from such compensation. In addition, Emerging Grow=
th Stock Alert intends to receive three million five hundred thousand unre=
stricted shares of WSCH from a third party for the publication of this rep=
ort and additional services related to WSCH. Be aware of an inherent=
conflict of interest due to our intent to profit from the liquidation of =
these shares. Part or all of this position may be sold at any time, even a=
fter we have made positive statements regarding the above company. A=
ll factual information in this report was gathered from public source=
s, including but not limited to SEC filings, Company Press Releases, and t=
he company's website at wasatchpharm.com. Emerging Growth Stock Alert=
believes this information to be reliable but can make no guarantee as to =
its accuracy or completeness. Use of the material within this email consti=
tutes your acceptance of these terms.=
| | =
To be r=
emoved from future mailings, please reply to this email with "Remove&=
quot; in the subject line |
| |